Article

Alcon, at 76.9% of WaveLight shares, moves forward with acquisition

Huenenberg, Switzerland-Alcon Inc. had gained control of 76.9% of WaveLight’s approximately 6.6 million issued and outstanding shares as of Sept. 28.

Huenenberg, Switzerland-Alcon Inc. had gained control of 76.9% of WaveLight’s approximately 6.6 million issued and outstanding shares as of Sept. 28. As required by the German Security Purchase and Take-over Act, an additional 2-week acceptance period began Sept. 29 and will continue through Oct. 12.

“We expect more WaveLight shareholders will accept our offer during this additional 2-week acceptance period,” said Cary Rayment, Alcon’s chairman, president, and chief executive officer (CEO).

The company has received approvals from the competition authorities in Germany and Austria and is awaiting cartel clearances in China, Cyprus, and Spain prior to closing of the transaction.

“Once we obtain the other regulatory approvals, we can begin the process of integrating WaveLight with Alcon’s existing refractive business,” Rayment said.

Alcon had amended its original acquisition offer, removing the minimum acceptance threshold level of 75% and extending the tender offer period to Sept. 25. The company was offering €15 per WaveLight share, a 100% premium on the 1-month (€7.49) and a 118% premium on the 3-month (€6.88) volume-weighted average stock exchange price as of the July 16 publication of the decision to launch the tender offer.

Through Sept. 25, about 3.1 million WaveLight shares were tendered to Alcon, equal to 47.1% of the issued and outstanding WaveLight shares. Additionally, Alcon legally acquired 1.96 million WaveLight shares, or 29.9% of the issued and outstanding shares, either on the stock market or through direct purchase.

“Alcon’s friendly takeover offer is in the best interest of WaveLight shareholders, and I am glad that the offer reached such a high level of acceptance,” said Max Reindl, WaveLight’s CEO.

For the latest information, see http://www.alcon.com/investors-media/us-canada.asp.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.